Search Results - "Perez Persona, Ernesto"

Safety of switching from intravenous to subcutaneous rituximab during first‐line treatment of patients with non‐Hodgkin lymphoma: the Spanish population of the MabRella study by García‐Muñoz, Ricardo, Quero, Cristina, Pérez‐Persona, Ernesto, Domingo‐García, Abel, Pérez‐López, Cristina, Villaescusa‐de‐la‐Rosa, Teresa, Martínez‐Castro, Ana M., Arguiñano‐Pérez, José M., Parra‐Cuadrado, Juan F., Panizo, Carlos

“…Summary Rituximab is a standard treatment for non‐Hodgkin diffuse large B‐cell (DLBCL) and follicular (FL) lymphomas. A subcutaneous formulation was developed…”
Get full text

Primary plasma cell leukaemia presenting with flower‐shaped nuclei by De Miguel Sánchez, Carlos, Robles de Castro, Diego, Pisón Herrero, Carlos, Pérez Persona, Ernesto, Salcedo Cuesta, Laura, Guinea de Castro, José M.

Get full text

A glimpse into relapsed refractory multiple myeloma treatment in real-world practice in Spain: the GeminiS study by Ríos-Tamayo, Rafael, Soler, Juan Alfons, García-Sánchez, Ricarda, Pérez Persona, Ernesto, Arnao, Mario, García-Guiñón, Antoni, Domingo, Abel, González-Pardo, Miriam, de la Rubia, Javier, Mateos, María Victoria

“…To describe the incorporation of monoclonal antibodies (mAb) in real-world (RW) practice for the treatment of patients with relapsed refractory multiple…”
Get full text

Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM) by González-Rincón, Julia, Garcia-Vela, José A, Gómez, Sagrario, Fernández-Cuevas, Belén, Nova-Gurumeta, Sara, Pérez-Sanz, Nuria, Alcoceba, Miguel, González, Marcos, Anguita, Eduardo, López-Jiménez, Javier, González-Barca, Eva, Yáñez, Lucrecia, Pérez-Persona, Ernesto, de la Serna, Javier, Fernández-Zarzoso, Miguel, Deben, Guillermo, Peñalver, Francisco J, Fernández, María C, de Oteyza, Jaime Pérez, Andreu, M Ángeles, Ruíz-Guinaldo, M Ángeles, Paz-Arias, Raquel, García-Malo, M Dolores, Recasens, Valle, Collado, Rosa, Córdoba, Raúl, Navarro-Matilla, Belén, Sánchez-Beato, Margarita, García-Marco, José A

“…Chronic Lymphocytic Leukemia (CLL) is the most prevalent leukemia in Western countries and is notable for its variable clinical course. This variability is…”
Get full text

Treatment burden in multiple myeloma according to comorbidity in real life by Pérez Persona, Ernesto, Oiartzabal Ormategui, Itziar, Cuevas Palomares, Laida, Santamaría López, Ana, Robles de Castro, Diego, Miguel de Sánchez, Carlos, Gabilondo Jalón, Miren, Pisón Herrero, Carlos, Unamunzaga Cilaurren, Ariane, Vega González de Viñaspre, Ana, Guinea de Castro, Jose María

Get full text

High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance by García-Marco, José A, Jiménez, Javier López, Recasens, Valle, Zarzoso, Miguel Fernández, González-Barca, Eva, De Marcos, Nieves Somolinos, Ramírez, M Jose, Parraga, Francisco Javier Peñalver, Yañez, Lucrecia, De La Serna Torroba, Javier, Malo, Maria Dolores Garcia, Ariznavarreta, Guillermo Deben, Persona, Ernesto Perez, Guinaldo, M Angeles Ruiz, De Paz Arias, Raquel, Llanos, Elena Bañas, Jarque, Isidro, Valle, M Del Carmen Fernandez, Tatay, Ana Carral, De Oteyza, Jaime Perez, Martin, Eva Maria Donato, Fernández, Inmaculada Perez, Martinez, Rafael Martinez, Costa, M Angeles Andreu, Champ, Diana, Suarez, Julio García, Díaz, Marcos González, Ferrer, Secundino, Carbonell, Félix, García-Vela, José A

“…It has been postulated that monitoring measurable residual disease (MRD) could be used as a surrogate marker of progression-free survival (PFS) in chronic…”
Get full text

Velcadito: Low dose of bortezomib with melphalan and prednisone for ≥75‐year‐olds newly diagnosed with multiple myeloma by Pérez‐Persona, Ernesto, Oiartzabal‐Ormategui, Itziar, Herraez, Susana, Menchaca, Carmen, Cuevas‐Palomares, Laida, Santamaría‐López, Ana, Díez‐Angulo, Rosana, Robles‐Castro, Diego, Miguel‐Sánchez, Carlos, Gabilondo‐Jalón, Miren, Pisón‐Herrero, Carlos, Unamunzaga‐Cilaurren, Ariane, Vega González‐Viñaspre, Ana, Salcedo‐Cuesta, Laura, Mendizabal‐Abad, Arantza, Guinea de Castro, José María

Get full text

Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells by Pérez‐Persona, Ernesto, Mateo, Gema, García‐Sanz, Ramón, Mateos, María‐Victoria, De Las Heras, Natalia, De Coca, Alfonso García, Hernández, José M., Galende, Josefina, Martín‐Nuñez, Guillermo, Bárez, Abelardo, Alonso, José M., Martín, Alejandro, López‐Berges, Consuelo, Orfao, Alberto, San Miguel, Jesús F., Vidriales, María‐Belén

“…Summary The present study explored the impact of two novel criteria; having >95% abnormal plasma cells by flow cytometry at diagnosis and the evolving subtype…”
Get full text

Pomalidomide, Cyclophosphamide, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Real-World Analysis of the Pethema-GEM Experience by Rodriguez-Otero, Paula, Sirvent, Maialen, González-Rodríguez, Ana Pilar, Lavilla, Esperanza, de Coca, Alfonso García, Arguiñano, José María, Martí, Josep M., Cabañas, Valentin, Motlló, Cristina, de Cabo, Erik, Encinas, Cristina, Murillo, Ilda, Hernández-Rivas, Jose Ángel, Pérez-Persona, Ernesto, Casado, Felipe, Sampol, Antonia, García, Ricarda, Blanchard, María Jesús, Anguita, Magdalena, Lafuente, Ana Paz, Iñigo, Belén, López, Aurelio, Ribas, Paz, Arnao, Mario, Maldonado, Roberto, Bladé, Joan, Mateos, María Victoria, Lahuerta, Juan José, San Miguel, Jesús F.

“…Treatment of relapsed/refractory multiple myeloma (RRMM) is highly challenging, especially for patients with disease refractory to initial therapy, and in…”
Get full text

Ultrafast 30-min infusion of a rituximab biosimilar (Truxima) by Pérez-Persona, Ernesto, Cuevas Palomares, Laida, Unamunzaga Cilaurren, Ariane, Gutiérrez López de Ocáriz, Xabier, Buendía Ureña, Buenaventura, Vega González de Viñaspre, Ana, Benito Ibarrondo, Begoña, Molinillo Fernández, María Carmen, Cordero Osúa, Ana, Benítez Delgado, Beatriz, García Albás, Juan José, Andrés Moralejo, Miguel Ángel, Guinea de Castro, José María

“…In this clinical trial, we demonstrate that ultrarapid fast infusion of rituximab (Truxima) in 30 min with oral premedication is feasible and secure for…”
Get full text

New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells by Pérez-Persona, Ernesto, Vidriales, María-Belén, Mateo, Gema, García-Sanz, Ramón, Mateos, Maria-Victoria, de Coca, Alfonso García, Galende, Josefina, Martín-Nuñez, Guillermo, Alonso, José M., de las Heras, Natalia, Hernández, José M., Martín, Alejandro, López-Berges, Consuelo, Orfao, Alberto, San Miguel, Jesús F.

“…Monoclonal gammopathy of uncertain significance (MGUS) and smoldering multiple myeloma (SMM) are plasma cell disorders with a risk of progression of…”
Get full text

Assessment of the psychometric properties of the Spanish version of EORTC QLQ-MY20 and evaluation of health-related quality of Life outcomes in patients with relapsed and/or refractory multiple myeloma in the real-world setting in Spain: results from the CharisMMa study by Dachs, Laura Rosiñol, Gaisán, Carmen Montes, Bustamante, Gabriela, López, Sebastián Garzón, García, Esther González, Persona, Ernesto Pérez, González-Calle, Verónica, Auzmendi, Maialen Sirvent, Pérez, José Maria Arguiñano, González Montes, Yolanda, Ríos Tamayo, Rafael, de Miguel Llorente, Dunia, Bernal, Luis Palomera, Mayol, Antonia Sampol, Caro, Carmen Couto, Grande, Marta, Fernández-Nistal, Alonso, Naves, Andrea, Miguel, Enrique M Ocio San

“…We evaluated the psychometric properties of the Spanish version of the European Organization for Research and Treatment of Multiple Myeloma (MM) specific…”
Get full text

Real-World Health Care Services Utilization Associated With the Management of Patients With Relapsed and Refractory Multiple Myeloma in Spain: The CharisMMa Study by Ocio, Enrique M., Montes-Gaisán, Carmen, Bustamante, Gabriela, Garzón, Sebastián, González, Esther, Pérez-Persona, Ernesto, González-Calle, Verónica, Sirvent, Maialen, Arguiñano, José M., González, Yolanda, Ríos, Rafael, de Miguel, Dunia, Grande, Marta, Fernández-Nistal, Alonso, Naves, Andrea, Rosiñol, Laura

“…Most patients with multiple myeloma (MM) relapse or become refractory, resulting in high health care costs. However, real-world data regarding the utilization…”
Get full text

Geriatric assessment in hematology scale predicts treatment tolerability in older patients diagnosed with hematological malignancies: The RETROGAH study by de la Rubia, Javier, González, Bernardo, Cruz-Jentoft, Alfonso J., Iglesias, Lorena, Jarque, Isidro, Persona, Ernesto Pérez, Lluch, Rafael, Marrero, Carmen, Zudaire, Maite, Gironella, Mercedes, Hernández-Rivas, José Ángel, Arnan, Montserrat, Olivier, Carmen, Encinas, Cristina, Soler, Juan Alfonso, Payer, Ángel Ramírez, Casado, Alfonso, Fernández, Patricia, Vilanova, David, Bonanad, Santiago

“…The GAH (Geriatric Assessment in Hematology) scale is a psychometrically valid tool aimed at identifying older patients with hematological malignancies at…”
Get full text

Treatment patterns and outcomes in real-world transplant-ineligible patients newly diagnosed with multiple myeloma by Cejalvo, María José, Bustamante, Gabriela, González, Esther, Vázquez-Álvarez, Judith, García, Ricarda, Ramírez-Payer, Ángel, Pérez-Persona, Ernesto, Abella, Eugenia, Garzón, Sebastián, García, Antoni, Jarque, Isidro, González, Marta Sonia, Sampol, Antonia, Motlló, Cristina, Martí, Josep María, Alcalá, Magdalena, Duro, Rafael, González, Yolanda, Sastre, José Luis, Sarrà, Josep, Lostaunau, Giselle, López, Rocío, de la Rubia, Javier

“…Despite the significant proportion of older patients with newly diagnosed multiple myeloma (MM), most clinical trials driving therapeutic decisions in routine…”
Get full text

Treatment patterns and outcomes among nontransplant newly diagnosed multiple myeloma patients in Spain by Hernández-Rivas, José-Ángel, Arnao, Mario, Arguiñano Pérez, José Maria, Rubio, Araceli, García, Esther Gónzalez, de Miguel, Dunia, Cherepanov, Dasha, Romanus, Dorothy, Verleger, Katharina, Johnson, Courtney, Corman, Shelby L, Grande, Marta, Persona, Ernesto Pérez

“…To describe treatment patterns and outcomes in nontransplant newly diagnosed multiple myeloma (NDMM) patients in Spain. This retrospective study included two…”
Get full text

Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies by Tamariz-Amador, Luis-Esteban, Battaglia, Anna Martina, Maia, Catarina, Zherniakova, Anastasiia, Guerrero, Camila, Zabaleta, Aintzane, Burgos, Leire, Botta, Cirino, Fortuño, Maria-Antonia, Grande, Carlos, Manubens, Andrea, Arguiñano, Jose-Maria, Gomez, Clara, Perez-Persona, Ernesto, Olazabal, Iñigo, Oiartzabal, Itziar, Panizo, Carlos, Prosper, Felipe, San-Miguel, Jesus F., Rodriguez-Otero, Paula, Martín-Sánchez, Esperanza, Paiva, Bruno

“…There is evidence of reduced SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies. We hypothesized that tumor and treatment-related…”
Get full text

Immune dysfunction prior to and during vaccination in multiple myeloma: a case study based on COVID-19 by Martín-Sánchez, Esperanza, Tamariz-Amador, Luis-Esteban, Guerrero, Camila, Zherniakova, Anastasiia, Zabaleta, Aintzane, Maia, Catarina, Blanco, Laura, Alignani, Diego, Fortuño, Maria-Antonia, Grande, Carlos, Manubens, Andrea, Arguiñano, Jose-Maria, Gomez, Clara, Perez-Persona, Ernesto, Olazabal, Iñigo, Oiartzabal, Itziar, Panizo, Carlos, Prosper, Felipe, San-Miguel, Jesus F., Rodriguez-Otero, Paula, Paiva, Bruno

“…Infection is the leading cause of death in multiple myeloma (MM). However, the cellular composition associated with immune dysfunction is not defined. We…”
Get full text

Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial by Puig, Noemi, Hernández, Miguel T., Rosiñol, Laura, González, Esther, de Arriba, Felipe, Oriol, Albert, González-Calle, Verónica, Escalante, Fernando, de la Rubia, Javier, Gironella, Mercedes, Ríos, Rafael, García-Sánchez, Ricarda, Arguiñano, José M., Alegre, Adrián, Martín, Jesús, Gutiérrez, Norma. C., Calasanz, María J., Martín, María L., Couto, María del Carmen, Casanova, María, Arnao, Mario, Pérez-Persona, Ernesto, Garzón, Sebastián, González, Marta S., Martín-Sánchez, Guillermo, Ocio, Enrique M., Coleman, Morton, Encinas, Cristina, Vale, Ana M., Teruel, Ana I., Cortés-Rodríguez, María, Paiva, Bruno, Cedena, M. Teresa, San-Miguel, Jesús F., Lahuerta, Juan J., Bladé, Joan, Niesvizky, Ruben, Mateos, María-Victoria

“…Although case-control analyses have suggested an additive value with the association of clarithromycin to continuous lenalidomide and dexamethasone (Rd), there…”
Get full text

P1552: AN IMMUNE ATLAS OF THE DYSFUNCTIONAL CELLULAR AND ANTIBODY RESPONSE TO COVID‐19 VACCINATION IN HEMATOLOGICAL PATIENTS WITH A MATURE B‐CELL NEOPLASM by Martín‐Sánchez, Esperanza, Guerrero, Camila, Tamariz‐Amador, Luis‐Esteban, Zherniakova, Anastasiia, Zabaleta, Aintzane, Maia, Catarina, Blanco, Laura, Fortuño, Maria‐Antonia, Grande, Carlos, Manubens, Andrea, Arguiñano, Jose‐Maria, Perez, Clara Gomez, Persona, Ernesto Perez, Eizaguirre, Iñigo Olazabal, Oiartzabal, Itziar, Panizo, Carlos, Prosper, Felipe, Miguel, Jesús San, Rodríguez‐Otero, Paula, Paiva, Bruno

Get full text